Home › Esophageal Adenocarcinoma › South Dakota
Pag-aaral pangklinika para sa Esophageal Adenocarcinoma sa South Dakota
5 pag-aaral para sa Esophageal Adenocarcinoma ang naghahanap ng mga kalahok sa mga site sa South Dakota.
Mga Lungsod sa South Dakota
Opisyal na teksto ng pag-aaral (English)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Rapid City Regional Hospital, Rapid City
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- at 5 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05677490Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Avera Cancer Institute, Sioux Falls
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06324357Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Sioux Falls
- Research Site, Yankton
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07431281A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.